Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Clinterooon Oct 16, 2013 12:22pm
71 Views
Post# 21820261

RE:Letter to shareholders...

RE:Letter to shareholders...
DayofReckoning

Why do you say it will be 2 years before revenue from skin lightener? Where does it say that in the Letter from the CEO?

The letter states “Our short term focus is to formalize each of the LOIs that we have signed, confirming Sirona Biochem's first commercial transactions and predictable revenue streams.”

Therefore, this is a short term goal. What exactly is short term is anyone’s guess but it would not be reasonable to say short term is 24 months.

I am confused about the share price action over the past two days. It doesn’t seem to warrant such a drop but the market is like that. At least many can now realize the foolishness of posters that continually come here and talk about $10, etc.  Those comments have absolutely no foundation… but they are popular.

Anyway, I am going to use this as a buying opportunity. Once an agreement is finalized there will certainly be a pop in share price.
Bullboard Posts